Home › Gliosarcoma
Pag-aaral pangklinika para sa Gliosarcoma na nagre-recruit sa U.S.
11 pag-aaral para sa Gliosarcoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT03896568ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07089641A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Nagre-recruitPhase 1
Edad 19 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05698524Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06934889Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Nagre-recruitPhase 1
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT04991870HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 8, 2026 · NCT07301268Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 4, 2026 · NCT05756985Study of Pembrolizumab and M032 (NSC 733972)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 22, 2026 · NCT05084430Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 12, 2026 · NCT05465954Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 18, 2025 · NCT04541082Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.